PROGRAMME OF LIVE SESSIONS: CET timing
The programme below will take place live. This time schedule corresponds to CET timing. Click here to adapt the
CET time schedule to your own time zone.
If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge
and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated
below.
Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To
interact you must be online at the times indicated in the programme below.
Thank you for joining us. We wish you a good meeting
ESH
EUROPEAN
SCHOOLOF
HAEMATOLOGY
E-Conference: 2nd How to Diagnose and Treat
CML / MPN
February 25-28, 2021 – #ESHCMLMPN2021
Chairs: Claire Harrison, Andreas Hochhaus, Ruben Mesa
Thursday, February 25th, 2021
Friday
13:55-14:00 Welcome
SESSION I – Optimizing cytoreduction
Chair: Jean-Jacques Kiladjian (Paris)
14:00-14:05 Introduction Jean-Jacques Kiladjian (Paris)
14:05-14:15 Interactive case Jean-Jacques Kiladjian (Paris)
14:15-14:35 Case-based lecture: Hydroxyurea / Resistance to Hydroxyurea Alessandro Vannucchi (Florence)
14:35-14:55 Case-based lecture: Interferon Heinz Gisslinger (Vienna)
14:55-15:15 Case-based lecture: use of ruxolitinib in essential Brady L. Stein (Chicago)
Thrombocythemia and Splanchnic vessel thrombosis
15:15-15:25 Interactive case: Hepcidin Agonists in Polycythemia Vera Marina Kremyanskaya (New York)
15:25-15:30 Addition of Parsaclisib (INCB050465), a PI3Kδ inhibitor, in Abdulraheem Yacoub (Kansas City)
patients with suboptimal response to ruxolitinib: a phase 2
study in patients with Myelofibrosis
15:30-16:00 Panel discussion
16:00-16:10 Coffee Break
1
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES